Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3-day IV vs 3-day IV + 7-day Oral Antibiotics for Acute Pyelonephritis in Children
NCT05544565Phase 4Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2023
- Primary completion
- Jan 2028
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ceftriaxone, amikacin, trimethoprim + sulfamethoxazole and cefixime in acute pyelonephritis (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Recurrence of febrile urinary tract infection at 28 days. Started Mar 2023; status: recruiting.
02
Drugs
ceftriaxoneamikacintrimethoprim + sulfamethoxazolecefixime
03
Conditions
acute pyelonephritis
Beyond the preview
Go deeper on NCT05544565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05544565.